A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci177813 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Guokun Zhang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Information Processing, Biometry, and Epidemiology, Medical Faculty, Ludwig Maximilians University (LMU), Munich, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, German Federal Ministry of Education and Research.
Abstract (Originalsprache)
BACKGROUNDEndocrine therapy (ET) with tamoxifen (TAM) or aromatase inhibitors (AI) is highly effective against hormone receptor-positive (HR-positive) early breast cancer (BC), but resistance remains a major challenge. The primary objectives of our study were to understand the underlying mechanisms of primary resistance and to identify potential biomarkers.METHODSWe selected more than 800 patients in 3 subcohorts (Discovery, n = 364, matched pairs; Validation 1, n = 270, Validation 2, n = 176) of the West German Study Group (WSG) ADAPT trial who underwent short-term preoperative TAM or AI treatment. Treatment response was assessed by immunohistochemical labeling of proliferating cells with Ki67 before and after ET. We performed comprehensive molecular profiling, including targeted next-generation sequencing (NGS) and DNA methylation analysis using EPIC arrays, on posttreatment tumor samples.RESULTSTP53 mutations were strongly associated with primary resistance to both TAM and AI. We identified distinct DNA methylation patterns in resistant tumors, suggesting alterations in key signaling pathways and tumor microenvironment composition. Based on these findings and patient age, we developed the Predictive Endocrine ResistanCe Index (PERCI). PERCI accurately stratified responders and nonresponders in both treatment groups in all 3 subcohorts and predicted progression-free survival in an external validation cohort and in the combined subcohorts.CONCLUSIONOur results highlight the potential of PERCI to guide personalized endocrine therapy and improve patient outcomes.TRIAL REGISTRATIONWSG-ADAPT, ClinicalTrials.gov NCT01779206, retrospectively registered 01-25-2013.FUNDINGGerman Cancer Aid (Grant Number 70112954), German Federal Ministry of Education and Research (Grant Number 01ZZ1804C, DIFUTURE).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Medical Information Processing, Biometry, and Epidemiology, Medical Faculty, Ludwig Maximilians University (LMU), Munich, Germany.
- Institute of Pathology, Hannover Medical School, Hannover, Germany.
- Institute of Sociology (IfS), Faculty of Social Sciences, University of Bremen, Bremen, Germany.
- Department of Methodology and Statistics, Faculty of Social & Behavioural Sciences, Utrecht University, Utrecht, Netherlands.
- Breast Center, Department OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany.
- Department of Human Genetics, Hannover Medical School, Hannover, Germany.
Förderung
- German Cancer Aid
- German Federal Ministry of Education and Research
Zitieren
APA
Zhang, G., Jurinovic, V., Bartels, S., Christgen, M., Christgen, H., Kandt, L. D., Mishieva, L., Ni, H., Raap, M., Klein, J., Katzke, A. L., Hofmann, W., Steinemann, D., Kates, R. E., Gluz, O., Graeser, M., Kümmel, S., Nitz, U., Plass, C., …, & Kreipe, H. H. (2025). A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders. Journal of Clinical Investigation. https://doi.org/10.1172/jci177813
Vancouver
Zhang G, Jurinovic V, Bartels S, Christgen M, Christgen H, Kandt LD, et al. A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders. Journal of Clinical Investigation. 2025. doi:10.1172/jci177813
BibTeX
@article{Zhang2025,
author = {Zhang, Guokun and Jurinovic, Vindi and Bartels, Stephan and Christgen, Matthias and Christgen, Henriette and Kandt, Leonie Donata and Mishieva, Lidiya and Ni, Hua and Raap, Mieke and Klein, Janin and Katzke, Anna-Lena and Hofmann, Winfried and Steinemann, Doris and Kates, Ronald E and Gluz, Oleg and Graeser, Monika and Kümmel, Sherko and Nitz, Ulrike and Plass, Christoph and Lehmann, Ulrich and Zu Eulenburg, Christine and Mansmann, Ulrich and Gerhäuser, Clarissa and Harbeck, Nadia and Kreipe, Hans H},
title = {A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci177813}
}
EUVIMED